Andreas Gunther
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.
Journal: Clinical pharmacology and therapeutics
Published: December 19, 2024
Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective.
Journal: Antibiotics (Basel, Switzerland)
Published: November 30, 2023
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: June 13, 2022
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam.
Journal: British journal of clinical pharmacology
Published: September 29, 2021
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers.
Journal: Expert opinion on investigational drugs
Published: June 28, 2021
Addressing Today's Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: June 03, 2021
Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.
Journal: Clinical pharmacology and therapeutics
Published: March 24, 2021
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
Journal: British journal of clinical pharmacology
Published: September 09, 2019
The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
Journal: Neuromuscular disorders : NMD
Published: June 22, 2018
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Journal: British journal of clinical pharmacology
Published: March 23, 2018
Early pediatric formulation development with new chemical entities: Opportunities of e-tongue besides human taste assessment.
Journal: International journal of pharmaceutics
Published: March 28, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026